Systemic effect of radiotherapy before or after nivolumab in lung cancer: an observational, retrospective, multicenter study

被引：10

作者：

Bassanelli, Maria ^{[1
]}

Ricciuti, Biagio ^{[2
]}

Giannarelli, Diana ^{[3
]}

Cecere, Fabiana Letizia ^{[4
]}

Roberto, Michela ^{[5
]}

Giacinti, Silvana ^{[6
]}

Barucca, Viola ^{[7
]}

Santarelli, Mario ^{[8
]}

Ruggeri, Enzo Maria ^{[9
]}

Marchetti, Paolo ^{[5
]}

Cognetti, Francesco ^{[10
,11
]}

Gelibter, Alain ^{[12
]}

Cortesi, Enrico ^{[12
]}

Chiari, Rita ^{[13
]}

Milella, Michele ^{[14
]}

Ceribelli, Anna ^{[1
]}

机构：

[1] San Camillo de Lellis Hosp, Dept Oncol, Viale JF Kennedy, I-2100 Rieti, Italy

[2] Azienda Osped Perugia, Santa Maria Misericordia Hosp, Dept Oncol, Perugia, Italy

[3] IRCSS Regina Elena Natl Canc Inst, Biostat Unit, Rome, Italy

[4] IRCSS Regina Elena Natl Canc Inst, Div Med Oncol 1, Rome, Italy

[5] Univ Rome Sapienza, Dept Oncol, Rome, Italy

[6] Belcolle Hosp Viterbo, Dept Oncol, Viterbo, Italy

[7] Misericordia Hosp, Dept Oncol, Grosseto, Italy

[8] San Camillo de Lellis Hosp, Dept Radiotherapy, Rieti, Lazio, Italy

[9] Belcolle Hosp AUSL Viterbo, Dept Oncol, Viterbo, Italy

[10] Regina Elena Inst Canc Res, Div Med Oncol 1, Rome, Italy

[11] Univ Roma La Sapienza, Dept Clin & Mol Med, Rome, Italy

[12] Policlin Umberto 1, Med Oncol Unit, Rome, Italy

[13] Azienda Osped Perugia, Santa Maria Misericordia Hosp, Dept Med Oncol, Perugia, Italy

[14] Integrated Univ Hosp Verona, Div Oncol, Verona, Italy

来源：

TUMORI JOURNAL | 2022年 / 108卷 / 03期

关键词：

Combined modality therapy; immunotherapy; lung cancer; radioimmunotherapy; radiotherapy; METASTATIC UROTHELIAL CARCINOMA; CLINICAL ACTIVITY; TUMOR-CELLS; SINGLE-ARM; RADIATION; IMMUNOTHERAPY; PEMBROLIZUMAB; THERAPY; AGE; IMMUNOSENESCENCE;

D O I：

10.1177/03008916211004733

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: The combination of radiotherapy (RT) and programmed death 1 inhibitors seems to increase antitumor immune responses. Objective: To assess the outcome and the role of the best combination sequence, i.e. immunotherapy given before, during, and/or after RT, in patients with non-small cell lung cancer (NSCLC). Methods: We conducted an observational, retrospective analysis of 95 consecutive patients with advanced NSCLC who received any radiotherapy treatment and nivolumab, as clinically indicated. Median overall survival (OS) and the 95% confidence interval (CI) were estimated with the Kaplan-Meier method. Cox model was used to obtain hazard ratio (HR) and associated 95% CI with statistical inference by log-rank statistic. Results: Median OS was 11.9 months (95% CI, 6.6-17.2). Patients who received radiotherapy during an immune checkpoint inhibitor treatment started more than 60 days before showed a better outcome than patients who started immunotherapy over 60 days after RT ending (HR, 2.90 [1.37-6.12], p = 0.005; median OS, 22.4 months vs 8.6 months, p = 0.005). Median progression-free survival was 6.3 months (95% CI, 4.6-8.0). Conclusions: This study shows that combining irradiation with nivolumab for the treatment of advanced NSCLC leads to improved OS. The optimal time window for the combination of RT and immunotherapy seems to play a critical role for therapeutic antitumor response derived by abscopal effect.

引用

页码：250 / 257

页数：8

共 43 条

[1] Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Kurata, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

Carpeno, J. de Castro ;

Faivre-Finn, C. ;

Reck, M. ;

Vansteenkiste, J. ;

Spigel, D. R. ;

Wadsworth, C. ;

Melillo, G. ;

Taboada, M. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (24) :2342-2350

[2] Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Yokoi, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

de Castro Carpeno, J. ;

Wadsworth, C. ;

Melillo, G. ;

Jiang, H. ;

Huang, Y. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) :1919-1929

[3] Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial [J].

Balar, Arjun V. ;

Galsky, Matthew D. ;

Rosenberg, Jonathan E. ;

Powles, Thomas ;

Petrylak, Daniel P. ;

Bellmunt, Joaquim ;

Loriot, Yohann ;

Necchi, Andrea ;

Hoffman-Censits, Jean ;

Perez-Gracia, Jose Luis ;

Dawson, Nancy A. ;

van der Heijden, Michiel S. ;

Dreicer, Robert ;

Srinivas, Sandy ;

Retz, Margitta M. ;

Joseph, Richard W. ;

Drakaki, Alexandra ;

Vaishampayan, Ulka N. ;

Sridhar, Srikala S. ;

Quinn, David I. ;

Duran, Ignacio ;

Shaffer, David R. ;

Eigl, Bernhard J. ;

Grivas, Petros D. ;

Yu, Evan Y. ;

Li, Shi ;

Kadel, Edward E., III ;

Boyd, Zachary ;

Bourgon, Richard ;

Hegde, Priti S. ;

Mariathasan, Sanjeev ;

Thastrom, AnnChristine ;

Abidoye, Oyewale O. ;

Fine, Gregg D. ;

Bajorin, Dean F. .

LANCET, 2017, 389 (10064) :67-76

[4] Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma [J].

Bellmunt, J. ;

de Wit, R. ;

Vaughn, D. J. ;

Fradet, Y. ;

Lee, J. -L. ;

Fong, L. ;

Vogelzang, N. J. ;

Climent, M. A. ;

Petrylak, D. P. ;

Choueiri, T. K. ;

Necchi, A. ;

Gerritsen, W. ;

Gurney, H. ;

Quinn, D. I. ;

Culine, S. ;

Sternberg, C. N. ;

Mai, Y. ;

Poehlein, C. H. ;

Perini, R. F. ;

Bajorin, D. F. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (11) :1015-1026

[5] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[6] Molecular analysis of the RET and NTRK1 gene rearrangements in papillary thyroid carcinoma in the Polish population [J].

Brzezianska, Ewa ;

Karbownik, Malgorzata ;

Migdalska-Sek, Monika ;

Pastuszak-Lewandoska, Dorota ;

Wloch, Jan ;

Lewinski, Andrzej .

MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2006, 599 (1-2) :26-35

[7] Radiation as an Immune Modulator [J].

Burnette, Byron ;

Weichselbaum, Ralph R. .

SEMINARS IN RADIATION ONCOLOGY, 2013, 23 (04) :273-280

[8] External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing [J].

Chakraborty, M ;

Abrams, SI ;

Coleman, CN ;

Camphausen, K ;

Schlom, J ;

Hodge, JW .

CANCER RESEARCH, 2004, 64 (12) :4328-4337

[9] Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy [J].

Chakraborty, M ;

Abrams, SI ;

Camphausen, K ;

Liu, KB ;

Scott, T ;

Coleman, CN ;

Hodge, JW .

JOURNAL OF IMMUNOLOGY, 2003, 170 (12) :6338-6347

[10] Immune checkpoint inhibitors and elderly people: A review [J].

Daste, Amaury ;

Domblides, Charlotte ;

Gross-goupil, Marine ;

Chakiba, Camille ;

Quivy, Amandine ;

Cochin, Valerie ;

de Mones, Erwan ;

Larmonier, Nicolas ;

Soubeyran, Pierre ;

Ravaud, Alain .

EUROPEAN JOURNAL OF CANCER, 2017, 82 :155-166

← 1 2 3 4 5 →